The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET.

0833 GMT – Novo Nordisk’s Wegovy drug trial points to positive impacts over and above weight loss, turbocharging the outlook for so-called GLP-1 drugs, Citi analysts Peter Verdult and Andrew Baum write. The trial showed risk reductions in major adverse cardiovascular events were achieved regardless of age, gender, ethnicity and starting body mass index. “Importantly from a commercial perspective, the greatest benefit was seen in younger patients and lower BMI ranges.” Based on discussions over the weekend, Citi says that cardiologist/nephrologist’s willingness to embrace GLP-1 drugs in the treatment of their non-diabetic patients is set to increase markedly. “We also anticipate pressure on Medicare to provide access to Wegovy for the treatment of cardiovascular disease/chronic kidney disease.” Shares trade 3.5% higher at DKK715.50. ([email protected])